Paper Details

  1. Home
  2. Paper Details

Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman-Moore strain) manufactured in India.

Author: Ashwath NarayanaDoddabele Hanumanthaiah, AshwinBelludi Yajman, Gangaboraiah, GowdaGiriyanna, HollaRamesh, MadhusudanaShampur Narayana, ManjulaShamanna, PadhiAsutosh, PatelPradip Maganlal, RavishHaradanahalli Shankaraiah, SampathGadey, SatapathyDurga Madhab, SudarshanMysore Kalappa, TripathyRadhe Madhab

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated the safety and immunogenicity of Vaxirab-N, a purified chick embryo cell rabies vaccine, in healthy adults. The vaccine was found to be safe and immunogenic, with mild to moderate adverse events observed. The study recommends Vaxirab-N for rabies prophylaxis via both intramuscular and intradermal routes.
Paper Details　
Original Abstract of the Article :
Zydus Cadila Health care, India developed a new purified chick embryo cell rabies vaccine (PCECV, Vaxirab-N; 1 mL) by adapting Pitman-Moore strain of virus on to the chick embryo fibroblast cell line in 2006. During 2007-10, a series of safety and immunogenicity studies were conducted as per ICH-GCP...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181025/

データ提供：米国国立医学図書館（NLM）

Safety and Immunogenicity of Vaxirab-N Rabies Vaccine

Rabies, a deadly virus, is like a venomous scorpion lurking in the desert. This study evaluates the safety and immunogenicity of a new purified chick embryo cell rabies vaccine, Vaxirab-N, developed in India. The authors conducted a series of clinical trials, using [specific methodology], to assess the vaccine's effectiveness in generating protective antibodies against rabies. They evaluated the vaccine's safety profile, looking for any adverse reactions or side effects. Their research provides valuable data for informing the use of Vaxirab-N in rabies prophylaxis.

Vaxirab-N: A Promising New Rabies Vaccine

The clinical trials found [specific findings related to the safety and immunogenicity of Vaxirab-N], indicating that Vaxirab-N was well-tolerated and effectively generated protective antibodies against rabies. This suggests that Vaxirab-N could be a valuable tool in preventing rabies infections, particularly in areas where this disease is prevalent.

Staying Safe from Rabies

The findings of this study offer a beacon of hope in the fight against rabies. Vaxirab-N, like a sturdy camel caravan protecting travelers in the desert, may provide a vital shield against this deadly disease. However, it's important to remember that vaccination alone is not enough. Staying safe from rabies also requires avoiding contact with animals that may be infected, particularly wild animals. If you are bitten or scratched by an animal, seek medical attention immediately and follow your healthcare provider's instructions for post-exposure prophylaxis.

Dr. Camel's Conclusion

Vaxirab-N offers a promising new weapon in the fight against rabies, like a well-equipped camel caravan ready to face the dangers of the desert. This study provides valuable data for supporting its use in rabies prophylaxis, but it's crucial to continue monitoring its effectiveness and safety over time. Staying vigilant and taking necessary precautions are essential for preventing rabies infections and protecting both ourselves and our communities.

Date :
  1. Date Completed 2015-01-05
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24030586

DOI: Digital Object Identifier

PMC4181025

Related Literature

Article Analysis
・Side Effects of rabies vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.